Payment overview · 2025
General Payments
$228.76
13 reported records · 8 companies
Healthcare provider profile · identity verified
Nathan B. Allen, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LEON, IA · NPI 1629398987
Verified facts
What the public records show
CMS Open Payments records show Nathan B. Allen, D.O. received $228.76 in general payments during 2025 across 13 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.71 | 36.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.67 | 13.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.55 | 10.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.55 | 10.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.83 | 7.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.79 | 7.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.05 | 7.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.61 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $209.91 | 12 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $82.71 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.67 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 18 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 280 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
110 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
280 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
203 | 32 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 522 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 463 | 88 |
| Omeprazole | Omeprazole | 334 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 62 |
| Furosemide | Furosemide | 290 | 56 |
| Gabapentin | Gabapentin | 283 | 59 |
| Jardiance | Empagliflozin | 280 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 270 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 88 |
| Losartan Potassium | Losartan Potassium | 259 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 74 |
| Metformin Hcl | Metformin Hcl | 240 | 54 |
| Eliquis | Apixaban | 203 | 32 |
| Potassium Chloride | Potassium Chloride | 202 | 41 |
| Simvastatin | Simvastatin | 195 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 45 |
| Warfarin Sodium | Warfarin Sodium | 150 | 21 |
| Ozempic | Semaglutide | 146 | 35 |
| Spironolactone | Spironolactone | 135 | 29 |
| Xarelto | Rivaroxaban | 135 | 27 |
| Trazodone Hcl | Trazodone Hcl | 132 | 31 |
| Allopurinol | Allopurinol | 131 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 38 |
| Tramadol Hcl | Tramadol Hcl | 130 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 21 |
| Montelukast Sodium | Montelukast Sodium | 112 | 24 |
| Sertraline Hcl | Sertraline Hcl | 112 | 24 |
| Farxiga | Dapagliflozin Propanediol | 110 | 26 |
| Metformin Hcl Er | Metformin Hcl | 102 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 17 |
| Mirtazapine | Mirtazapine | 88 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 21 |
| Alprazolam | Alprazolam | 83 | 11 |
| Prednisone | Prednisone | 83 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 13 |
| Ezetimibe | Ezetimibe | 76 | 26 |
| Levetiracetam | Levetiracetam | 75 | suppressed |
| Lorazepam | Lorazepam | 75 | suppressed |
| Carvedilol | Carvedilol | 74 | 21 |
| Donepezil Hcl | Donepezil Hcl | 72 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 65 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 16 |
| Buspirone Hcl | Buspirone Hcl | 62 | suppressed |
| Chlorthalidone | Chlorthalidone | 58 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 56 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 24 |
| Atenolol | Atenolol | 50 | 16 |
| Memantine Hcl | Memantine Hcl | 48 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Latanoprost | Latanoprost | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 11 |
| Glipizide | Glipizide | 44 | suppressed |
| Meloxicam | Meloxicam | 43 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 12 |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 11 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Finasteride | Finasteride | 38 | 14 |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 27 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 29 |
| Timolol Maleate | Timolol Maleate | 36 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 15 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Victoza 3-Pak | Liraglutide | 27 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | 12 |
| Victoza 2-Pak | Liraglutide | 26 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Travoprost | Travoprost | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Azithromycin | Azithromycin | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Dofetilide | Dofetilide | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Betaseron | Interferon Beta-1b | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Copaxone | Glatiramer Acetate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $228.76 · 13 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, AUSTEDO XR, CAPVAXIVE, COMIRNATY, ENFLONSIA, GARDASIL 9, JARDIANCE, Kerendia, PREVNAR 20, TZIELD, UBRELVY | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error